RYAH Group Inc. (CSE: RYAH) Publishes Report Outlining Cannabis Treatments for Conditions Associated with HIV and AIDS

  • RYAH releases report outlining ways cannabis is being used to treat conditions associated with HIV and AIDS
  • Report data compiled by RYAH Data Ecosystem between January 1, 2018, and August 26, 2021
  • Data includes specific HIV and AIDS conditions, details cannabis strains used by patients 
  • Three-part RYAH Data Ecosystem includes volume control and management devices, QR tracking to identify product formulations and parameters, mobile apps to manage information and provide feedback

With a mission to advance remote-health solutions and analytics-based patient treatments across the world, RYAH Group (CSE: RYAH) (formerly RYAH Medtech) is the leader in volume control and management technology for plant-based medicine. The company recently released a report outlining cannabis treatment options to address symptoms and conditions associated with HIV and AIDS.

The report, titled “Cannabis Use For Conditions Associated With HIV and AIDS”, is based on data compiled by the RYAH Data Ecosystem between January 1, 2018, and August 26, 2021. Through the RYAH Data Ecosystem, patients were able to submit data outlining symptoms they addressed with the use of cannabis, in addition to detailing specific cannabis strains used to treat those conditions. 

Some of the conditions logged and analyzed by the RYAH Data Ecosystem included fatigue, cachexia (a disease characterized by loss of muscle mass), mental health issues, wasting syndrome, chronic pain, hepatitis C, nausea, and inflammation. Along with providing gender-specific details on the conditions experienced by users, the report also includes critical information on the diverse range of cannabis strains used by patients to treat each condition.

The ground-breaking report is part of RYAH’s data-driven mission to provide innovative plant-based medical treatments that leverage the use of loT (Internet of Things) dose-measuring devices and AI analytics applications. With a focus on collecting and building AI-powered data models, the company’s three-part ecosystem is designed to manage volumetrics and capture pertinent data in order to provide innovative plant-based medical treatments tailored to each patient. 

Each segment of RYAH’s Data Ecosystem builds upon the company’s goal to generate a flow of information that is critical to building AI-powered models that enhance treatment administration. The first section focuses on providing precision volume control solutions with the RYAH Patch, Inhaler, and Liquid Dispenser. The second segment leverages a QR tracking application to track product formulations and volume control parameters. The final segment features RYAH’s mobile applications that patients can use to provide feedback via their smart devices.

With a focus on predictive analytics in the global medical plant and nutraceutical intake industry, RYAH is dedicated to helping doctors and patients leverage the power of data to personalize plant-based treatments for better patient outcomes. Bolstered by a robust intellectual property portfolio and suite of portable, cost-effective products, the company is positioned to lead the industry in volume control and management technology for plant-based medicine.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://cnw.fm/RYAH 

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Archives

Select A Month

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722